GSK Drug Shows Promise in Treating Bone Cancer
A new clinical trial reveals that ris-rez significantly delays disease progression in patients with refractory osteosarcoma.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Do you believe pharmaceutical companies are successfully prioritizing the development of treatments for rare cancers?
GSK and Hansoh Pharmaceutical presented data showing their cancer drug ris-rez successfully delayed disease progression in patients with relapsed refractory osteosarcoma. The study indicates that the targeted therapy offers a substantial improvement in survival without disease worsening compared to standard chemotherapy.
Why it matters
The positive results are critical to GSK's strategic efforts to regain a competitive foothold in the oncology market. As the company accelerates development of this therapy, it aims to establish a stronger portfolio of advanced cancer treatments.
In a study of 122 patients aged 12 and older, those treated with 12-milligram doses of ris-rez lived a median of 5.5 months without disease worsening, compared to 1.4 months for chemotherapy. The trial demonstrates a 67% reduction in the risk of death or progression.
The players
GSK
This global pharmaceutical company is aggressively expanding its oncology portfolio to compete with other major manufacturers.
Hansoh Pharmaceutical
A major pharmaceutical developer based in China that collaborated with GSK to conduct the recent cancer drug clinical trial.
The details
The drug acts as a targeted therapy that delivers cell-killing agents directly to tumor sites to stop growth. This late-stage trial focused specifically on patients who had already failed to respond to more than two prior lines of treatment.
Timeline
October 26, 2026: Clinical data was presented at a medical meeting held in Madrid.
The Big Picture
This study is a core component of GSK's oncology research and development program as it seeks to scale its influence in global cancer treatment markets.
This drug provides a new, more effective option for patients with refractory osteosarcoma who have exhausted standard chemotherapy treatments. Ongoing development of this therapy could eventually change the standard of care for similar bone cancers globally.
The takeaway
Targeted therapies continue to outperform traditional chemotherapy in treating complex, drug-resistant cancers. Patients and their families should discuss emerging clinical trial options with their oncologists as these new medications advance through development.
Further reading
For more information on the latest advancements, visit the Cancer section.
Live Poll
Do you believe pharmaceutical companies are successfully prioritizing the development of treatments for rare cancers?
